Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 57.94m |
Free float | 50.26m |
P/E (TTM) | -- |
Market cap | 290.29m USD |
EPS (TTM) | -1.27 USD |
--
More ▼
Announcements
- Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
- Rezolute to Participate in Upcoming Investor Conferences
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
More ▼